Literature DB >> 16488505

Development of an ELISA for esRAGE and its application to type 1 diabetic patients.

Shigeru Sakurai1, Yasuhiko Yamamoto, Hironori Tamei, Hirokazu Matsuki, Ken-Ichi Obata, Li Hui, Junnosuke Miura, Mari Osawa, Yasuko Uchigata, Yasuhiko Iwamoto, Takuo Watanabe, Hideto Yonekura, Hiroshi Yamamoto.   

Abstract

We recently identified a naturally occurring soluble form of RAGE (the receptor for advanced glycation endproducts, receptor for AGE) in cultured human vascular cells, and named it endogenous secretory RAGE (esRAGE). esRAGE is generated by alternative RNA splicing and is able to capture AGE, and exerts protection against AGE-induced endothelial cell injury. In the present study, the presence of esRAGE in human circulation was demonstrated for the first time, and a highly sensitive and specific sandwich ELISA system for esRAGE was developed to see whether esRAGE could be related to an individual resistance to the development of diabetic vascular complications. Sera from 47 type 1 diabetic subjects without clinical nephropathy (urinary albumin excretion <300mg/g creatinine) and 55 healthy controls were analyzed by the ELISA. Circulating esRAGE concentrations in diabetic patients with simple and proliferative retinopathy (0.09+/-0.02ng/mL, n=16 and 0.08+/-0.02ng/mL, n=8, respectively) were significantly lower than in those without retinopathy (0.13+/-0.06ng/mL, n=23). The results indicate that esRAGE can be a useful biomarker to indicate individual variations in susceptibility to diabetic retinopathy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16488505     DOI: 10.1016/j.diabres.2005.12.013

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  17 in total

1.  Impaired osteogenic differentiation and enhanced cellular receptor of advanced glycation end products sensitivity in patients with type 2 diabetes.

Authors:  Mattabhorn Phimphilai; Peraphan Pothacharoen; Prachya Kongtawelert; Nipon Chattipakorn
Journal:  J Bone Miner Metab       Date:  2016-11-21       Impact factor: 2.626

2.  Prothrombin is a binding partner of the human receptor of advanced glycation end products.

Authors:  Genny Degani; Alessandra Altomare; Stefania Digiovanni; Beatrice Arosio; Guenter Fritz; Angela Raucci; Giancarlo Aldini; Laura Popolo
Journal:  J Biol Chem       Date:  2020-07-14       Impact factor: 5.157

3.  Identification of mouse orthologue of endogenous secretory receptor for advanced glycation end-products: structure, function and expression.

Authors:  Ai Harashima; Yasuhiko Yamamoto; Chunmei Cheng; Koichi Tsuneyama; Khin Mar Myint; Akihiko Takeuchi; Kazunobu Yoshimura; Hui Li; Takuo Watanabe; Shin Takasawa; Hiroshi Okamoto; Hideto Yonekura; Hiroshi Yamamoto
Journal:  Biochem J       Date:  2006-05-15       Impact factor: 3.857

4.  Endogenous secretory receptor for advanced glycation end products is associated with low serum interleukin-1 receptor antagonist and elevated IL-6 in older community-dwelling adults.

Authors:  Candace L Crasto; Richard D Semba; Kai Sun; Mansi Dalal; Anna Maria Corsi; Stefania Bandinelli; Jack M Guralnik; Luigi Ferrucci
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2011-02-28       Impact factor: 6.053

5.  Advanced glycation end products and their circulating receptors predict cardiovascular disease mortality in older community-dwelling women.

Authors:  Richard D Semba; Luigi Ferrucci; Kai Sun; Justine Beck; Mansi Dalal; Ravi Varadhan; Jeremy Walston; Jack M Guralnik; Linda P Fried
Journal:  Aging Clin Exp Res       Date:  2009-04       Impact factor: 3.636

6.  Elevated serum advanced glycation end products and poor grip strength in older community-dwelling women.

Authors:  Mansi Dalal; Luigi Ferrucci; Kai Sun; Justine Beck; Linda P Fried; Richard D Semba
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2009-01-31       Impact factor: 6.053

7.  Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity.

Authors:  Ayumi Yoshizaki; Kazuhiro Komura; Yohei Iwata; Fumihide Ogawa; Toshihide Hara; Eiji Muroi; Motoi Takenaka; Kazuhiro Shimizu; Minoru Hasegawa; Manabu Fujimoto; Shinichi Sato
Journal:  J Clin Immunol       Date:  2008-09-30       Impact factor: 8.317

8.  Endogenous Secretory RAGE as a Novel Biomarker for Metabolic Syndrome and Cardiovascular Diseases.

Authors:  Hidenori Koyama; Hiroshi Yamamoto; Yoshiki Nishizawa
Journal:  Biomark Insights       Date:  2007-09-17

9.  Involvement of TAGE-RAGE System in the Pathogenesis of Diabetic Retinopathy.

Authors:  Masayoshi Takeuchi; Jun-Ichi Takino; Sho-Ichi Yamagishi
Journal:  J Ophthalmol       Date:  2010-06-22       Impact factor: 1.909

10.  Advanced glycation end products and their circulating receptors and level of kidney function in older community-dwelling women.

Authors:  Richard D Semba; Luigi Ferrucci; Jeffrey C Fink; Kai Sun; Justine Beck; Mansi Dalal; Jack M Guralnik; Linda P Fried
Journal:  Am J Kidney Dis       Date:  2008-09-11       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.